Stage III cancers had significantly higher expression of CXCL2, CD69, CCR4, and TNFRsf13c, all of which have been implicated as potential therapeutic targets in other malignancies [26–30], or in the case of CCR4, poor prognosis in lung cancer [31]. Here, CXCL2 is linked to lung carcinoma.